Kewaunee Scientific ( (KEQU) ) has released its Q2 earnings. Here is a breakdown of the information Kewaunee Scientific presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Kewaunee Scientific Corporation is a global leader in designing, manufacturing, and installing laboratory, healthcare, and technical furniture products, serving both domestic and international markets with a diverse product portfolio aimed at outfitting modern laboratories.
In its second quarter of fiscal year 2025, Kewaunee Scientific reported a decrease in sales to $47.8 million, down 5.3% from the previous year. Despite this, net earnings rose to $3.0 million from $2.7 million, and diluted earnings per share increased to $1.01, driven by strong domestic performance.
The company’s domestic segment saw a sales increase of 6.5%, attributed to higher product demand, contributing to improved earnings. However, international sales experienced a significant drop of 30.1% due to construction delays in India. Additionally, the acquisition of Nu Aire, Inc. is expected to enhance Kewaunee’s capabilities in laboratory furnishings.
Kewaunee’s order backlog reached a historic high of $184.4 million, reflecting robust market demand and positioning the company for continued success. The acquisition of Nu Aire further supports this growth trajectory, promising expanded market reach and capabilities.
Looking forward, Kewaunee Scientific’s management remains optimistic about future performance, bolstered by a strong backlog and strategic acquisitions, which are expected to drive strong results for the remainder of the fiscal year.
